228 related articles for article (PubMed ID: 20371449)
21. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update.
Mackey AC; Green L; Leptak C; Avigan M
J Pediatr Gastroenterol Nutr; 2009 Mar; 48(3):386-8. PubMed ID: 19274799
[No Abstract] [Full Text] [Related]
22. Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti-tumor necrosis factor monotherapy.
Ong DE; Kamm MA; Hartono JL; Lust M
J Gastroenterol Hepatol; 2013 Oct; 28(10):1595-9. PubMed ID: 23662928
[TBL] [Abstract][Full Text] [Related]
23. The incidence of hepatosplenic T-cell lymphoma in a large managed care organization, with reference to anti-tumor necrosis factor therapy, Northern California, 2000-2006.
Herrinton LJ; Liu L; Abramson O; Jaffe ES
Pharmacoepidemiol Drug Saf; 2012 Jan; 21(1):49-52. PubMed ID: 21823196
[TBL] [Abstract][Full Text] [Related]
24. Lymphomatoid Papulosis Type B in a Patient with Crohn's Disease Treated with TNF-Alpha Inhibitors Infliximab and Adalimumab.
Medvecz M; Kiss N; Hársing J; Kuroli E; Hegede G; Csomor J; Kárpáti S; Marschalkó M
Acta Dermatovenerol Croat; 2019 Sep; 27(3):202-204. PubMed ID: 31542070
[TBL] [Abstract][Full Text] [Related]
25. Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine.
Navarro JT; Ribera JM; Mate JL; Granada I; Juncà J; Batlle M; Millá F; Feliu E
Leuk Lymphoma; 2003 Mar; 44(3):531-3. PubMed ID: 12688327
[TBL] [Abstract][Full Text] [Related]
26. [Response to stopping azathioprine in Crohn's patients on combined treatment with infliximab].
Martín De Carpi J; Varea V
An Pediatr (Barc); 2009 Mar; 70(3):271-7. PubMed ID: 19409244
[TBL] [Abstract][Full Text] [Related]
27. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease.
Dassopoulos T; Sultan S; Falck-Ytter YT; Inadomi JM; Hanauer SB
Gastroenterology; 2013 Dec; 145(6):1464-78.e1-5. PubMed ID: 24267475
[No Abstract] [Full Text] [Related]
28. An unusual presentation of T-lymphoma in a Crohn's disease patient treated with combo therapy: we are willing to take a risk of serious adverse events for a doubtful benefit?
Sinagra E; Romano C; Virdone R; Orlando E; Cottone M; Orlando A
J Crohns Colitis; 2012 Oct; 6(9):954-5. PubMed ID: 22771136
[No Abstract] [Full Text] [Related]
29. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
[TBL] [Abstract][Full Text] [Related]
30. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
[TBL] [Abstract][Full Text] [Related]
31. Infliximab use and hepatosplenic T cell lymphoma: questions to be asked and lessons learned.
Rosh JR; Oliva-Hemker M
J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):165-7. PubMed ID: 17255825
[No Abstract] [Full Text] [Related]
32. "In vitro" azathioprine-induced changes in peripheral T cell apoptosis and IFN-γ production associate with drug response in patients with Crohn's Disease.
Cossu A; Biancone L; Ascolani M; Pallone F; Boirivant M
J Crohns Colitis; 2013 Jul; 7(6):441-50. PubMed ID: 22840925
[TBL] [Abstract][Full Text] [Related]
33. Clinical features and treatment outcomes of 14 patients with hepatosplenic γ δ T-cell lymphoma.
Wang Q; Jiang Y; Zhu Q; Duan Y; Chen X; Xu T; Jin Z; Li C; Wu D; Huang H
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3441-3445. PubMed ID: 33856526
[TBL] [Abstract][Full Text] [Related]
34. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease.
Thayu M; Markowitz JE; Mamula P; Russo PA; Muinos WI; Baldassano RN
J Pediatr Gastroenterol Nutr; 2005 Feb; 40(2):220-2. PubMed ID: 15699701
[No Abstract] [Full Text] [Related]
35. [Microcellular lung carcinoma in patient with hepatosplenic T-cell lymphoma: a case report].
Kalac M; Ostojić S; Gasparov S; Planinc-Peraica A; Dominis M; Jaksić B
Lijec Vjesn; 2006; 128(3-4):76-8. PubMed ID: 16808095
[TBL] [Abstract][Full Text] [Related]
36. Phenotypic features of Crohn's disease associated with failure of medical treatment.
Moran GW; Dubeau MF; Kaplan GG; Yang H; Seow CH; Fedorak RN; Dieleman LA; Barkema HW; Ghosh S; Panaccione R;
Clin Gastroenterol Hepatol; 2014 Mar; 12(3):434-42.e1. PubMed ID: 23978351
[TBL] [Abstract][Full Text] [Related]
37. Hepatosplenic αβ T-cell lymphoma arising after long-term azathioprine therapy successfully treated with allogeneic bone marrow transplant.
Bašić Kinda S; Duraković N; Dotlić S; Serventi Seiwerth R; Davidović Mrsić S; Dubravčić K; Aurer I
Leuk Lymphoma; 2013 Jun; 54(6):1334-5. PubMed ID: 23083012
[No Abstract] [Full Text] [Related]
38. Regression of Hodgkin lymphoma after discontinuation of a tumor necrosis factor inhibitor for Crohn's disease: a case report and review of the literature.
Cassaday RD; Malik JT; Chang JE
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):289-92. PubMed ID: 21658658
[TBL] [Abstract][Full Text] [Related]
39. [Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis].
Sansó Sureda A; Rocamora Durán V; Sapiña Camaró A; Royo Escosa V; Bosque López MJ
Gastroenterol Hepatol; 2011 Oct; 34(8):546-50. PubMed ID: 21665330
[TBL] [Abstract][Full Text] [Related]
40. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
